Artificial and bioartificial liver devices: present and future
The DOI matches its Crossref record.
Abstract
Liver failure is associated with high morbidity and mortality without transplantation. There are two types of device for temporary support: artificial and bioartificial livers. Artificial livers essentially use non-living components to remove the toxins accumulated during liver failure. Bioartificial livers have bioreactors containing hepatocytes to provide both biotransformation and synthetic liver functions. We review here the operating principles, chemical effects, clinical effects and complications of both types, with specific attention paid to bioartificial systems. Several artificial support systems have FDA marketing authorisation or are CE labelled, but the improvement they provide in terms of patient clinical outcome has not yet been fully demonstrated. At present, different bioartifical systems are being investigated clinically on the basis of their promises and capacity to provide and replace most liver functions. However, important issues such as cost, cell availability, maintenance of cell viability and functionality throughout treatment, and regulatory issues, as well as difficult challenges, including implementing cell-housing devices at the patient’s bedside on an emergency basis, have delayed their appearance in intensive care units and on the market. Bioreactors are, nevertheless, when combined with artificial components, a pragmatic approach for future treatment of liver failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Acute-on chronic liver failure
Jalan, R., Gines, P., Olson, J. C., Mookerjee, R. P., Moreau, R., Garcia-Tsao, G., Arroyo, V., & Kamath, P. S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.026 · Cited by 646
Direct Reprogramming of Human Fibroblasts to Functional and Expandable Hepatocytes
Huang, P., Zhang, L., Gao, Y., He, Z., Yao, D., Wu, Z., Cen, J., Chen, X., Liu, C., Hu, Y., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.003 · Cited by 560
The therapeutic potential of mesenchymal stem cell‐derived extracellular vesicles
Katsuda, T., Kosaka, N., Takeshita, F., & Ochiya, T. (2013) · PROTEOMICS · doi:10.1002/pmic.201200373 · Cited by 423
Kribben, A., Gerken, G., Haag, S., Herget–Rosenthal, S., Treichel, U., Betz, C., Sarrazin, C., Hoste, E., Van Vlierberghe, H., Escorsell, À., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.056 · Cited by 409
Acute-on-chronic liver failure
Bernal, W., Jalan, R., Quaglia, A., Simpson, K., Wendon, J., & Burroughs, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00309-8 · Cited by 331
Suk, K. T., Yoon, J., Kim, M. Y., Kim, C. W., Kim, J. K., Park, H., Hwang, S. G., Kim, D. J., Lee, B. S., Lee, S. H., et al. (2016) · Hepatology · doi:10.1002/hep.28693 · Cited by 303
“6) New therapeutic approaches such as bio-artificial liver, stem cell therapy, and regenerative medicine are being investigated in an attempt to improve the prognosis of patients with liver cirrhosis.((7-9)) There has been increasing interest in the transplantation of bone marrow cells, hematopoietic stem cells, and m…”
BackgroundCell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
The MELD score in patients awaiting liver transplant: Strengths and weaknesses
Bernardi, M., Gitto, S., & Biselli, M. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.008 · Cited by 174
Biomedical Applications of Nondegradable Polymers
Subramaniam, A., & Sethuraman, S. (2014) · Natural and Synthetic Biomedical Polymers · doi:10.1016/b978-0-12-396983-5.00019-3 · Cited by 75
Wang, Y., Zheng, Q., Sun, Z., Wang, C., Cen, J., Zhang, X., Jin, Y., Wu, B., Yan, T., Wang, Z., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.03.013 · Cited by 55
Acute-on-chronic liver failure: far to go—a review
Luo, J., Li, J., Li, P., Liang, X., Hassan, H. M., Moreau, R., & Li, J. (2023) · Critical Care · doi:10.1186/s13054-023-04540-4 · Cited by 54
Wu, G., Wu, D., Lo, J., Wang, Y., Wu, J., Lu, S., Xu, H., Zhao, X., He, Y., Li, J., et al. (2020) · Biomaterials Science · doi:10.1039/c9bm01879d · Cited by 28
Bioartificial livers: a review of their design and manufacture
Tuerxun, K., He, J., Ibrahim, I., Yusupu, Z., Yasheng, A., Xu, Q., Tang, R., Aikebaier, A., Wu, Y., Tuerdi, M., et al. (2022) · Biofabrication · doi:10.1088/1758-5090/ac6e86 · Cited by 24
“Therefore, most BAL systems under clinical investigations, including HepatAssist, ELAD, AMC-BAL, BLSS, and MELS, are constructed based on hollow fiber bioreactors [4].”
The road to regenerative liver therapies: the triumphs, trials and tribulations
Raju, R., Chau, D., Verfaillie, C. M., & Hu, W.-S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.022 · Cited by 14
Stem Cell-Based Strategies: The Future Direction of Bioartificial Liver Development
Feng, L., Wang, Y., Fu, Y., Li, T., & He, G. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10672-5 · Cited by 9
“Cell transplantation and bioartificial liver (BAL) systems have emerged as alternative and effective methods to compensate for lost liver function and increase patient survival rate [6, 7].”
Metadata
- Authors
- Carpentier, B., Gautier, A., & Legallais, C.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2009-11-18
- Volume
- 58
- Issue
- 12
- Pages
- 1690-1702
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2103862050
- Cited by
- 213
- References
- 0
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.